Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Sells $19,941.99 in Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Jason A. Okazaki sold 1,569 shares of Assembly Biosciences stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $12.71, for a total value of $19,941.99. Following the completion of the transaction, the chief executive officer now directly owns 16,423 shares of the company’s stock, valued at $208,736.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Assembly Biosciences Stock Up 2.7 %

Shares of ASMB opened at $13.15 on Friday. The stock’s fifty day simple moving average is $13.23 and its 200-day simple moving average is $11.19. Assembly Biosciences, Inc. has a 12-month low of $7.69 and a 12-month high of $20.04.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned 0.08% of Assembly Biosciences at the end of the most recent reporting period. Institutional investors own 19.92% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ASMB shares. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st. StockNews.com upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, April 5th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.